ANIX - Anixa Bio says its COVID-19 compounds are expected to be effective against Omicron variant

Anixa Biosciences (NASDAQ:ANIX) announces the results of a genomic variant analysis done with its partner, MolGenie, GmbH, on potential compounds to treat COVID-19. ANIX shares up 2.2% premarket at $3.20. The data indicate that the compounds in development should be effective against the Omicron variant, in addition to the previously identified Delta variant of the virus. In order to evaluate the efficacy of these compounds against the Omicron variant, Anixa and MolGenie performed an analysis of the corresponding Mpro enzyme of the variant. "We have identified and synthesized several compounds that exhibit potency against the Mpro enzyme in in-vitro biological assays. We are now initiating comprehensive pharmacokinetic analyses of these compounds to evaluate their suitability as therapies,"  said Dr. Lutz Weber, President and CEO of MolGenie.

For further details see:

Anixa Bio says its COVID-19 compounds are expected to be effective against Omicron variant